RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Cost Effectiveness of Treatment Sequences for Elderly Metastatic Colorectal Cancer Patients: A Seer-Medicare-Based Modelling Analysis
A Seer-Medicare-Based Modelling Analysis [MEETING ABSTRACT PCN91]
Parikh, R., Du, XL., Morgan, RO., & Lairson, DR. (2016). Cost Effectiveness of Treatment Sequences for Elderly Metastatic Colorectal Cancer Patients: A Seer-Medicare-Based Modelling Analysis: A Seer-Medicare-Based Modelling Analysis [MEETING ABSTRACT PCN91]. Value in Health, 19(3), A150. https://doi.org/10.1016/j.jval.2016.03.1590
Treatment sequences with bevacizumab at first-line and targeted biologics at third-line may not be cost-effective at the commonly used threshold of $100,000/QALY gained but a marginal decrease in the cost of bevacizumab may make treatment sequences with first-line bevacizumab cost-effective. Future economic evaluations should validate the study results using parameters from ongoing clinical trials.